Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab

Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab

Abstract The checkpoint inhibitor nivolumab is active in patients with metastatic melanoma who have failed ipilimumab. In this phase I/II study, we assessed nivolumab's safety in 92 ipilimumab-refractory patients with unresectable stage III or IV melanoma, including those who experienced grade...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Jeffrey S. Weber, Geoffrey T. Gibney, Ragini R. Kudchadkar, Bin Yu, Pingyan Cheng, Alberto J. Martinez, Jodie Kroeger, Allison Richards, Lori McCormick, Valerie E. Moberg, Heather Cronin, Xiuhua Zhao, Michael J. Schell, Y. Ann Chen
Materialtyp: Artigo
Språk:engelska
Publicerad: 2016
Länkar:https://doi.org/10.1158/2326-6066.cir-15-0193
https://cancerimmunolres.aacrjournals.org/content/canimm/4/4/345.full.pdf
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Internet

https://doi.org/10.1158/2326-6066.cir-15-0193
https://cancerimmunolres.aacrjournals.org/content/canimm/4/4/345.full.pdf

Liknande verk